Abstract The Mazdutide 10mg peptide pen (also known as IBI362 or LY3305677) features a synthetic, long-acting analogue of mammalian Oxyntomodulin (OXM). As a dual-agonist, Mazdutide activates both the Glucagon-like Peptide-1 (GLP-1) receptor and the Glucagon Receptor (GCGR). Unlike “twincretins” (such as Tirzepatide) which pair GLP-1 with GIP to promote storage buffering, Mazdutide pairs GLP-1 with Glucagon to drive energy expenditure. This 10mg formulation is specifically engineered for metabolic research focused on the “caloric burn” hypothesis, allowing researchers to investigate the synergy between GLP-1 mediated appetite suppression and Glucagon-mediated thermogenesis/lipolysis without the rapid degradation profile of native oxyntomodulin.

Mechanism and Research Interest

Primary Biological Pathway: Thermogenesis via GCGR The defining characteristic of Mazdutide is its potent activation of the Glucagon Receptor. While native glucagon is hyperglycaemic, Mazdutide utilises this pathway to increase Resting Energy Expenditure (REE). Research utilising the 10mg pen focuses on the upregulation of Uncoupling Protein 1 (UCP1) in brown adipose tissue (BAT) and the “beiging” of white adipose tissue. This mechanism allows for the investigation of weight loss driven by increased metabolic rate rather than solely by caloric restriction.

Secondary Research Finding: Hepatic Lipid Clearance Mazdutide is a primary candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH) research. The Glucagon component acts directly on hepatocytes to stimulate lipid oxidation and inhibit de novo lipogenesis. The 10mg formulation is critical for quantifying the rapid reduction of intrahepatic triglyceride content (IHTC). Studies often compare Mazdutide against mono-agonists to demonstrate the superior speed of liver fat reduction conferred by the glucagon moiety.

Tertiary Research Finding: Counter-Regulatory Glycaemic Balance A key physiological question is how Mazdutide maintains euglycaemia despite administering a glucagon agonist. Research indicates that the GLP-1 component (which stimulates insulin secretion) effectively counterbalances the glycogenolytic effect of the glucagon component. Researchers use the 10mg pen to challenge this balance in models of insulin resistance, monitoring continuous glucose profiles to verify that the net effect is a reduction in HbA1c and improved insulin sensitivity.

Long-term Genomic and Safety Observations Safety pharmacology studies regarding Mazdutide focus on cardiovascular parameters. Glucagon receptor activation is associated with positive chronotropy (increased heart rate). Longitudinal studies using the 10mg dose monitor heart rate variability (HRV) and blood pressure to establish the therapeutic window where metabolic benefits occur without adverse cardiac strain. Genomic profiling is also conducted to ensure that the upregulation of thermogenic genes does not trigger systemic oxidative stress.

Product Specifications

• Purity: Validated at >98+% via High-Performance Liquid Chromatography (HPLC). The acylated structure is verified to ensure protection against DPP-4 degradation and proper albumin binding.

• Appearance: The 3ml pen contains a clear, colourless, sterile liquid.

• Precision: The pen device features a micro-click adjustment, allowing for 0.25mg or 0.5mg dosing increments. This high resolution is vital for titration, as the Glucagon receptor can be sensitive to rapid dose escalations.

• Storage: The product must be stored at 2∘C to 8∘C.

Storage and Shipping Guidelines

Refrigeration and Shelf Life The Mazdutide 10mg Pen relies on a stable tertiary structure to maintain dual-receptor affinity. It must be refrigerated (2∘C to 8∘C) immediately upon receipt. The shelf life is 12 months in the sealed state. Once the bacteriostatic seal is broken, the solution is stable for 28 days. Researchers should note that Glucagon-based peptides can be prone to fibrillation; therefore, the pen should not be shaken vigorously.

Shipping Stability We utilise medical-grade thermal packaging. The peptide is stable for up to 72 hours at ambient UK temperatures during transit. However, due to the specific sensitivity of the glucagon-binding domain, we strongly recommend “Next Day” delivery to ensure the reagent arrives with maximal bioactivity.

Freezing Warning Strictly avoid freezing. Freezing causes the formation of ice crystals that can denature the peptide. Upon thawing, a denatured peptide may form insoluble fibrils (appearing as cloudiness or floating strands). Such a product is biologically inactive and must be discarded.

Why Choose the Peptide Pro 3ml Pen Format?

The Mazdutide 10mg Pen is the definitive tool for Investigating the “Energy Burn” Hypothesis. Investigating Glucagon receptor agonism is complex; manual mixing errors can easily lead to overdosing, resulting in unwanted hyperglycaemic spikes or tachycardia in test subjects.

Our pre-calibrated pen format eliminates this risk. It provides a sterile, controlled delivery system that ensures the ratio of GLP-1 to Glucagon activity remains constant for every administration. This consistency is the only way to generate publishable data on the delicate balance of oxyntomodulin analogues.

For researchers expanding their metabolic portfolio, we recommend comparing data against:

• Survodutide 10mg: (For comparative Glucagon/GLP-1 structural research).

• Tirzepatide 20mg: (To compare “Energy Expenditure” vs. “Lipid Partitioning” mechanisms).

Disclaimer

This product is strictly for Research Use Only (RUO). It is not intended for human consumption, injection, therapeutic use, or diagnostic procedures. The information provided is for educational and scientific reference only. Purchase is restricted to verified research institutions and qualified individuals. Any evidence of intended misuse for human application will result in immediate order cancellation and blacklisting, in compliance with UK research chemical regulations.